entinostat

Drug Overview

Entinostat is a modern, oral medication categorized as a Targeted Therapy. It is currently being studied for its ability to treat various forms of advanced cancer. Unlike traditional chemotherapy that kills all fast-growing cells, entinostat is a “Smart Drug” that changes how cancer cells behave and how the immune system sees them. It belongs to a specialized group of drugs called HDAC inhibitors, which focus on the genetic “control switches” inside a cell.

• Generic Name: Entinostat (also known as SNDX-275)
• US Brand Names: None (Currently an Investigational Drug)
• Drug Class: Benzamide Histone Deacetylase (HDAC) Inhibitor
• Route of Administration: Oral (Tablet)
• FDA Approval Status: Investigational. It has received Breakthrough Therapy Designation from the FDA for specific types of breast cancer but is not yet approved for general prescription use outside of clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

Entinostat works as an “epigenetic therapy.” This means it does not change your DNA itself, but it changes how your cells “read” the instructions in your DNA.

Molecular Level Activity

Inside every cell, DNA is wrapped around proteins called histones. For a cell to read a gene (like a gene that stops cancer from growing), the DNA must be unwrapped and loose. Enzymes called Histone Deacetylases (HDACs) act like “glue” that keeps the DNA wrapped tightly, preventing the cell from reading important anti-cancer instructions.

1. Enzyme Targeting: Entinostat specifically targets and blocks Class I and IV HDACs (specifically HDAC 1, 2, and 3).
2. Unwrapping the DNA: By blocking these enzymes, the drug allows the DNA to unwrap. This “turns on” tumor-suppressor genes that the cancer had previously “turned off.”
3. Stopping Growth: Once these genes are active again, they can signal the cancer cell to stop dividing or to undergo programmed cell death.
4. Immunotherapy Characteristic: Entinostat also changes the environment around the tumor. It reduces the number of “suppressor cells” (cells that hide the cancer from the immune system). This allows the body’s natural “soldier” cells (T-cells) to find and attack the tumor more effectively.

FDA-Approved Clinical Indications

As of early 2026, entinostat does not have final FDA approval for standard use. However, it is a primary candidate in several high-level research areas:

Oncological uses (Investigational):

• Advanced Breast Cancer: Specifically HR-positive, HER2-negative breast cancer in combination with hormone therapies.
• Non-Small Cell Lung Cancer (NSCLC): Studied in combination with other targeted drugs.
• Melanoma: Investigated for use alongside other immunotherapies.
• Renal Cell Carcinoma (Kidney Cancer): Evaluated for patients who have not responded to other treatments.

Non-oncological uses:

• There are currently no non-cancer uses for this medication.

Dosage and Administration Protocols

Because entinostat is investigational, the dose is determined by the specific clinical trial protocol. It is unique because it is usually taken only once a week.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Specific data for patients with severe kidney or liver disease is still being gathered. Currently, doctors monitor liver enzymes and kidney function weekly and may pause the drug if levels become abnormal.
• Blood Counts: If white blood cells or platelets drop too low, the weekly dose may be delayed or reduced.

Clinical Efficacy and Research Results

Recent clinical data (2020–2025) have focused on entinostat’s ability to “sensitize” tumors to other treatments.

• Breast Cancer (E2112 Trial): In studies of patients with advanced HR+ breast cancer, adding entinostat to hormonal therapy was shown to change the tumor environment. While it did not always extend overall survival for every patient, a significant group of patients saw their disease stabilize for longer periods.
• Immunotherapy Combinations: In 2024, data from melanoma and lung cancer trials suggested that entinostat could help “re-start” the immune system in patients who had stopped responding to other immunotherapies (like PD-1 inhibitors).
• Numerical Trends: Research indicates that roughly 25% to 30% of patients in specific combination trials experienced a clinical benefit, meaning their tumors either shrank or stopped growing for at least 6 months.

Safety Profile and Side Effects

Entinostat has a unique safety profile. Because it is taken weekly, some side effects may be less constant than daily medications.

Black Box Warning: None. (As an investigational drug, it has not yet been assigned a formal Black Box Warning).

Common side effects (>10%)

• Nausea and Vomiting: Usually mild and occurring on the day of treatment.
• Fatigue: A general feeling of tiredness or lack of energy.
• Diarrhea: Managed with standard over-the-counter medications.
• Decreased Appetite: Loss of interest in food.

Serious adverse events

• Neutropenia: A dangerous drop in white blood cells which increases infection risk.
• Thrombocytopenia: A drop in platelets that can lead to easy bruising or bleeding.
• Anemia: Low red blood cell counts causing shortness of breath.

Management Strategies: Patients are often given anti-nausea medication to take before their weekly dose. If blood counts drop, the doctor will pause the drug for a week to allow the bone marrow to recover.

Research Areas

Current research into entinostat is heavily focused on Combination Immunotherapy. While not a direct stem cell therapy, scientists are investigating how entinostat can “prime” the bone marrow to produce more effective immune cells. By changing the chemical signals in the tumor, researchers hope to use entinostat to make “cold” tumors (cancers the immune system ignores) become “hot” tumors (cancers the immune system attacks).

Patient Management and Practical Recommendations

Pre-treatment tests to be performed:

• Complete Blood Count (CBC): To ensure your blood levels are safe before starting.
• Liver Function Tests (LFTs): To check how well your liver is working.
• Pregnancy Test: Entinostat can harm an unborn baby.

Precautions during treatment:

• Avoid Grapefruit: Grapefruit juice can increase the amount of medicine in your blood to unsafe levels.
• Infection Control: Since your white blood cell count may drop, wash your hands often and avoid crowds or people who are sick.

“Do’s and Don’ts” list:

• DO take the pill on the same day every week to keep the medicine at a steady level.
• DO report a fever over 38°C (100.4°F) immediately, as this could be a sign of a low white blood cell count.
• DON’T stop taking the medication without talking to your oncologist, even if you feel tired.
• DON’T take extra doses if you miss a week; wait and call your doctor for instructions.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Entinostat is an investigational drug and is not FDA-approved for standard use. Always consult with a qualified oncologist regarding your specific diagnosis and treatment. In case of a medical emergency, contact your local emergency services immediately.